Methyl-b-cyclodextrin (MbCD) reduces lysosomal cholesterol accumulation in Niemann-Pick disease type C1 (NPC1) patient fibroblasts. However, the pharmacological activity of MbCD reported by different laboratories varies. To determine the potential causes of this variation, we analyzed the mass spectrum characteristics, pharmacological activity of three preparations of MbCDs, and the protein expression profiles of NPC1 patient fibroblasts after treatment with different sources of MbCDs. Our data revealed varied mass spectrum profiles and pharmacological activities on the reduction of lysosomal cholesterol accumulation in NPC1 fibroblasts for these three preparations of MbCDs obtained from different batches and different sources. Furthermore, a proteomic analysis showed the differences of these three MbCD preparations on amelioration of dysregulated protein expression levels in NPC1 cells. The results demonstrate the importance of prescreening of different cyclodextrin preparations before use as a therapeutic agent. A combination of mass spectrum analysis, measurement of pharmacological activity, and proteomic profiling provides an effective analytical procedure for characterization of cyclodextrins for therapeutic applications.
INTRODUCTION
N iemann-Pick disease type C (NPC) is an inherited, progressive neurodegenerative disorder caused by mutations in either the NPC1 or NPC2 gene, each of which encodes two distinct lysosomal cholesterolbinding proteins. 1, 2 Deficiency in NPC1 or NPC2 protein results in malfunction of intracellular cholesterol trafficking and accumulation of unesterified cholesterols in late endosomes/lysosomes. 3, 4 The clinical manifestations of NPC include hepatosplenomegaly and progressive neurodegeneration, a hallmark of the disease. 3 Currently, there is no effective treatment for NPC disease, although a number of agents have shown the therapeutic potential for treatment of NPC, including 2-hydroxypropyl-b-cyclodextrin (HPbCD), an analog of methyl-b-cyclodextrin (MbCD), and miglustat. [5] [6] [7] [8] [9] [10] [11] [12] [13] Several other treatments for NPC disease are currently being investigated, including histone deacetylase (HDAC) inhibitors and the c-Abl inhibitor, imatinib. [14] [15] [16] [17] [18] [19] Cyclodextrin showed remarkable in vivo efficacy in reduction of neurodegeneration and increase in life span of npc1 -/-mice. [20] [21] [22] [23] Cyclodextrins are cyclic oligosaccharides consisting of multiple glucopyranose units. Cyclodextrins typically exist as hexamers (a-cyclodextrins), heptamers (b-cyclodextrins), or octamers (g-cyclodextrins); all are highly water soluble with hydrophobic cavities of different sizes ( Fig. 1) . Originally used as a Food and Drug Administrationapproved excipient for pharmaceutical formulations of lipophilic compounds, HPbCDs fortuitously also show pharmacological activity. Both MbCD and HPbCD have been reported to reduce lysosomal cholesterol accumulation and enlarged lysosomes in NPC patient cells. [24] [25] [26] [27] HPbCD is currently in clinical trials for the treatment of NPC. 28, 29 However, the reported efficacy and potency of b-cyclodextrins varied between different laboratories. 4, [30] [31] [32] [33] [34] These differences could be caused by variations of HPbCD and MbCD preparations from the manufacture processes.
To develop an analytical method for selection of an effective cyclodextrin preparation as a therapeutic agent, we tested three preparations of MbCDs for their profiles with mass spectrometry (MS) analysis, pharmacological activity, and protein expression levels in NPC1 patient cells. We found that average molecular weights and levels of methylation in side chains of MbCD molecules are different in these three preparations obtained from two vendors and each from a different batch. The higher level of methylation is likely to be more efficient at reducing unesterified cholesterol accumulation in lysosomes of NPC1 patient cells. Further proteomic profiling analysis revealed that MbCD ameliorates dysregulated protein expression in NPC1 disease cells, including proteins involving lysosome formation, vesicle expansion, and completion during autophagy, SNARE interactions in vesicular transport, and steroid biosynthesis. These results demonstrate that the combination of mass spectrum profiling, pharmacologic activity on reduction of lysosomal cholesterol accumulation, and the signature of ameliorating abnormal protein expression in NPC1 patient cells is a useful analytic method for characterization and selection of high efficacy cyclodextrin preparations for use as a therapeutic agent.
MATERIALS AND METHODS

Materials
Three different sources of MbCDs were used for the experiments. The first batch of MbCD (MbCD-1) was purchased from MP Biochemicals 
Cells and Cell Culture
NPC1 patient skin fibroblasts (NPC1, ILE1061THR, GM03123) and human wild-type (WT) fibroblasts (GM05659) were purchased from the Coriell Cell Repository (Camden, NJ). The fibroblasts were cultured in Dulbecco's modified Eagle medium (Life Technologies) supplemented with 10% fetal bovine serum 
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(Life Technologies), 50 units/mL of penicillin, and 50 mg/mL streptomycin in a humidified incubator with 5% CO 2 at 37°C.
Amplex-Red Cholesterol Assay
Total cholesterol in patient cells was measured using the Amplex Ò Red cholesterol assay kit (catalog No. A12216; Life
Technologies, Carlsbad, CA). This biochemical assay uses an enzyme-coupled reporting system for detection of cholesterol concentrations in samples. It can be used to measure unesterified cholesterol (free cholesterol) and cholesteryl esters in blood samples and cell lysates. Cholesteryl esters in the samples are hydrolyzed by cholesterol esterase to free cholesterol, which is then oxidized by cholesterol oxidase to yield H 2 O 2 and the corresponding ketone product. H 2 O 2 is then detected by an enzyme-coupled report system using horseradish peroxidase and profluorescence substrate 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red reagent). A fluorescent product resorufin is produced by this enzyme-coupled report system. Cells were seeded in black, clear bottom, tissue culturetreated 96-well plates (catalog No. 655090; Greiner Bio-One) at a density of 2,500 cells/well in 100 mL of medium and cultured for 24 h. Compounds dissolved in the media were added to cells in the assay plates at 100 mL/well and incubated for another 4 days. The cells were then washed twice with Hank's Balanced Salt Solution (Life Technologies) and 100 mL/ well of reagent mixture from the Amplex Red cholesterol assay kit was added. Fluorescence intensity in assay plates after 1 h of incubation at 37°C was measured at an excitation wavelength of 560 (-10 nm) and emission wavelength of 590 (-10 nm) in a fluorescence plate reader (Tecan, Durham, NC) or ViewLux Ò plate reader (PerkinElmer).
Filipin Fluorescence Staining of Free Cholesterol
Filipin dye (catalog No. F9765; Sigma) is a polyene macrolide antibiotic and antifungal compound. It has been used as a profluorescence probe to stain the free cholesterol in cells or tissues, but not the esterified cholesterols at an appropriate concentration. 35 Briefly, cells were seeded at 2,000 cells/well in 100 mL of medium in black, clear bottom, tissue culturetreated 96-well plates and cultured for 24 h. Compounds dissolved in the media were added to the cells in the assay plates at 100 mL/well and incubated for another 4 days. 
ATP Content Assay for Cell Viability Measurement
An ATP content assay kit (ATPLite; PerkinElmer) was used to measure cell viability to assess compound cytotoxicity. ATP is present in all metabolically active cells. The ATP concentration declines rapidly when cell death occurs. This assay method utilizes a luciferase report system to measure cellular ATP level that is proportional to viable cell numbers and cell health conditions. The advantages of this ATP content assay include high assay sensitivity and one-step addition homogeneous assay format. Briefly, cells were seeded at 2,500 cells/ well in 100 mL medium in white, solid 96-well plates (catalog No. 655083; Greiner Bio-One) and incubated for 24 h. Cells were cultured and treated as described above for the cholesterol assay. After 4 days of incubation, 150 mL/well of ATP content reagent mixture (prepared according to the manufacturer's instructions) was added to the assay plates, followed by incubation at room temperature for 30 min protected from light. The luminescence signal was determined in the luminescence mode of the ViewLux plate reader.
Data Analysis and Statistics
Image analysis of filipin staining and LysoTracker red staining was conducted using IN Cell Analyzer software (version 3.7.2; GE Healthcare). The Multi-Target Analysis protocol was used for quantification of Hoechst-stained nuclei, LysoTracker red-stained lysosomes, EthD-1-stained nuclei, and filipin-stained unesterified cholesterol. Concentrationresponse curves were analyzed and IC 50 values calculated using Prism software (GraphPad, Inc., San Diego). Results in the figures are expressed as means of triplicates -standard deviations. Unless otherwise stated, an unpaired t-test was used to test for significance, with *P < 0.05, **P < 0.01, and ***P < 0.001.
MS Analysis of MbCD
To identify the average molecular weight and levels of methylation in side chains of MbCD molecules, we carried out the MS analysis. Initially, 0.4 mg of MbCD powder was dissolved in 3 mL of deionized Millipore (Sigma-Aldrich, St. Louis, MO) water as the stock solution (100 mM). An aliquot of the MbCD stock solution was further diluted with 90% methanol to 10 mg/mL (8 mM) for MS analysis. The diluted MbCD solution was directly infused into the API-4000 Mass Spectrometer (Applied Biosystems, Forster City, CA) at a rate of 10 mL/min. The mass spectrometer was used for Q1 scan with positive ion electrospray mode at 5000V and 100V declustering potential. The MS scan range was adjusted from m/z 1,200 to 1,450 at a scan rate of 2 s. The data analysis was performed by Analyst 1.5.1 software (Applied Biosystems, Foster City, CA).
Proteomic MS Analysis
Preparation of protein samples for liquid chromatography-tandem mass spectrometry analysis. MS proteomic analysis has been widely used to analyze biological samples and to quantitate protein levels in samples. For example, changes of cellular protein levels can be detected quantitatively in patient cells compared with WT control cells. To further understand the cholesterol reduction effect of MbCD, we carried out a proteomic analysis of NPC1 patient fibroblasts after treatment with MbCD.
NPC1 (GM03123) and WT (GM05659) fibroblasts (1 · 10 6 cells) were seeded into tissue culture-treated T-75 flasks; cells were treated with different sources of MbCDs (250 mM). After 4 days of treatment, cells were collected using TrypLEÔEx-press (Life Technologies) and washed with DPBS twice. Cell pellets were collected by centrifugation at 250 g for 5 min and stored at -80°C before sending to Poochon Scientific for proteomic MS analysis. Total protein extraction from cells was prepared by the following method. In brief, cell pellets were lysed in 0.4 mL lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 2% sodium dodecyl sulfate), followed by sonication. The cell lysate was clarified by centrifugation at 15,000 g for 10 min and supernatant was collected and stored at -80°C for further analysis. The protein concentration of the supernatant was determined by a BCAÔ Reducing Reagent compatible assay kit (Thermo Scientific, Rockford, IL).
Equal amounts of protein (130 mg) from each sample were fractioned by separation on NuPAGE 4%-12% Bis-Tris Gel (Life Technologies); 16 gel fractions from each lane representing one sample were treated with dithiothreitol (DTT) for reduction, then iodoacetamide for alkylation, and further digested with trypsin in 25 mM NH 4 HCO 3 solution. The digested protein was extracted as described elsewhere. 36 The extracted peptides were dried and reconstituted in 20 mL of 0.1% formic acid before the nanospray liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed.
Nanospray LC-MS/MS analysis. Sixteen tryptic peptide fractions from one cell sample were analyzed sequentially using a Thermo Scientific Q-ExactiveÔ hybrid QuadrupoleOrbitrapÔ Mass Spectrometer equipped with a Thermo Dionex UltiMate Ò 3000 RSLCnano System. Tryptic peptide samples were loaded onto a peptide trap cartridge at a flow rate of 5 mL/min. The trapped peptides were eluted onto a reversed-phase 25-cm C18 PicoFrit column (New Objective, Woburn, MA) using a linear gradient of acetonitrile (3%-36%) in 0.1% formic acid. The elution duration was 110 min at a flow rate of 0.3 mL/min. Eluted peptides from the PicoFrit column were ionized and sprayed into the mass spectrometer using a Nanospray FlexÔ Ion Source ES071 (Thermo Fisher) under the following settings: spray voltage, 1.6 kV, and capillary temperature, 250°C. The Q-Exactive instrument was operated in the data-dependent mode to automatically switch between full-scan MS and MS/MS acquisition. Survey full-scan MS spectra (m/z 300-2000) were acquired in the Orbitrap with 70,000 resolution (m/z 200) after the accumulation of ions to a 3 · 10 6 target value based on predictive automatic gain control (AGC) from the previous full scan. Dynamic exclusion was set to 20 s. The 12 most intense multiply-charged ions (z ‡ 2) were sequentially isolated and fragmented in the Axial higher energy collision-induced dissociation (HCD) cell using normalized HCD collision energy at 25% with an AGC target 1e5 and a maxima injection time of 100 ms at 17,500 resolution.
LC-MS/MS data analysis. The raw MS files were analyzed using the Thermo Proteome DiscovererÔ 1.4.1 platform (Thermo Scientific; Bremen, Germany) for peptide identification and protein assembly. For each cell sample, 16 raw MS files obtained from 16 sequential LCMS analyses were grouped for a single database search against the Human UniProtKB/Swiss-Prot human protein sequence databases (20,608 entries, as of December 20, 2015) based on the SEQUEST and percolator algorithms through the Proteome Discoverer 1.4.1 platform. Carbamidomethylation of cysteines was set as a fixed modification. The minimum peptide length was specified to be five amino acids. The precursor mass tolerance was set to 15 ppm, whereas fragment mass tolerance was set to 0.05 Da. The maximum false peptide discovery rate was specified as 0.01 or 0.05. The resulting Proteome Discoverer Report contains all assembled proteins with peptide sequences and matched spectrum counts. Protein quantification used the normalized spectral abundance factor (NSAF) method 37, 38 to calculate the protein relative abundance.
Pathway analysis. The cell functions are executed and regulated by entire sets of proteins (the proteome). The regulation of different cellular functions has been categorized into a number of signaling pathways, such as cell cycle and apoptosis. In each pathway, components are usually named according to their function: ligands, receptors, activating regulators, inhibitory regulators, and effectors. To measure the activation strength of a pathway, proteins classified as ligand, receptors, activating regulators, or inhibitory regulators were grouped and their relative abundances (ppm) were summed. The protein list for all analyzed pathways and processes was obtained from the KEGG pathway database (www.genome.jp/kegg/ pathway.html) and their functional annotations were manually confirmed using the UniProtKB protein database, the NCBI protein database, or available publications.
RESULTS
MbCD MS Analysis
Beta-cyclodextrins are complex molecules with a mixture with various positions and amounts of substitution groups.
Hence, the details of cyclodextrins vary between manufacturers and between different batches by the same manufacturer. Variations between preparations of b-cyclodextrins used as therapeutic agents for the treatment of human disease can lead to variations in the efficacy of these treatments. To characterize the molecular profiles of MbCD preparations, we measured the profiles of mass spectrum of these three MbCD preparations (MbCD-1, MbCD-2, and MbCD-3).
Methyl substitutions of the MbCD-1 sample range from 7 (7-Me) as the lowest methyl substitution to 15 (15-Me) as the highest (Fig. 2A) . The most abundant methyl-b-cyclodextrin is 10-Me, followed by 11-Me and 9-Me, while the lowest and highest methyl substitutions of MbCD-2 are 8-Me and 17-Me (Fig. 2B) . The distribution of methyl-b-cyclodextrins in MbCD-2 is more spread out than the other two preparations. For MbCD-2, the most abundant methyl-b-cyclodextrin is 13-Me, followed by 12-Me and 14-Me. The distribution of methyl-b-cyclodextrins in MbCD-3 seems to be less spread out than MbCD-1 and MbCD-2; the distribution from 13-Me to 18-Me is shown in Figure 2C . Interestingly, the most abundant methyl-b-cyclodextrin is 14-Me, followed by 15-Me and 16-Me, respectively, for the MbCD-3 preparation.
MS response of individual methyl-b-cyclodextrins was assumed to be nearly equal since the size and polarity of the molecules are close to each other. The average exact molecular weights of three MbCDs are determined by these MS analyses, by first measuring the signal height of the sodium adduct molecular ion of each methyl-b-cyclodextrin, then calculating the molecular distribution, and finally determining the molecular weight contribution (component) in Table 1 . MbCD-1 has the lowest molecular weight, followed by MbCD-2, while MbCD-3 has the highest molecular weight. These results indicated that all three MbCD preparations are different in the number of substitution groups and average molecular weights.
Reduction of Lysosomal Cholesterol Accumulation in NPC1 Fibroblasts by MbCD
Filipin staining of lysosomal unesterified cholesterols in NPC1 patient fibroblasts is used for diagnosis of the disease and for evaluation of therapeutic activity of the compounds. The effect of b-cyclodextrins on decreasing filipin staining and lysosomal cholesterol accumulation in NPC1 cells has been reported previously. 25, 39 To determine if these three MbCD preparations reduce lysosomal cholesterol accumulation, we measured their effect on filipin staining in NPC1 fibroblasts. While the lysosomal filipin staining was significantly increased in NPC1 fibroblasts, treatment with MbCDs reduced filipin staining in NPC1 fibroblasts (Fig. 3A) . MbCD-3 significantly reduced filipin staining with IC 50 of 19.2 mM. However, much weaker activities were found for MbCD-1 and MbCD-2 ( Fig. 3A-C) . The maximal inhibitory effect on cholesterol accumulation was 48.1% for MbCD-3 compared with 17.8% for MbCD-1 and 20.9% MbCD-2 ( Table 2) . Similar results were observed in two other independent experiments. MbCD-1 and -3 were obtained from the same vendor with different lot numbers (suggesting that they were manufactured in different times); nonetheless, their activities were significantly different. These results revealed significant differences in MbCD pharmacological efficacy among three preparations.
We also measured cellular cholesterol levels in NPC1 cells using an Amplex Red cholesterol assay. The Amplex Red cholesterol assay is a biochemical assay utilizing an enzyme-coupled reporting system to quantitatively measure both free cholesterol and cholesteryl esters. MbCD-3 reduced the cellular unesterified cholesterol levels in NPC1 fibroblasts in a concentration-dependent manner, similar to previous reports. 26 The IC 50 value of MbCD-3 for reduction of cellular cholesterol level was 14.4 mM. Similarly, as seen in the filipin staining experiment, efficacies of MbCD-1 and MbCD-2 were much weaker compared with that of MbCD-3.
The maximum inhibitory effect was 46.0% for MbCD-3, but Table 1 ). Abundance of lower number of methyl substitution of MbCD is shown in (A) (MbCD-1), while middle substitution is in (B) (MbCD-2) and higher substitution is in (C) (MbCD-3). 10-Me, 10 methylation to b-cyclodextrin molecule.
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was only 15.2% for MbCD-1 and 19.5% for MbCD-2 ( Fig. 4A , B, and Table 2 ). We observed similar results in two other independent experiments. We also determined cytotoxicity effects of MbCDs using an ATP content assay, but did not observe any toxic effect of these three preparations at the highest compound concentration of 300 mM (Fig. 4C) .
Decrease of Enlarged Lysosomes in NPC1 Fibroblasts by MbCD
The lysosomes are usually enlarged in NPC1 patient cells due to accumulation of cholesterols that can be detected using LysoTracker dye staining. 26 To further determine the pharmacological activity of three MbCD preparations, we measured LysoTracker dye staining in NPC1 fibroblasts [40] [41] [42] [43] [44] [45] To further examine the activity of MbCD on dysregulated protein expression in NPC1 cells, we carried out a proteomic analysis of protein expression in the NPC1 fibroblasts after treatment with MbCD. We identified a panel of 19 proteins that were dysregulated in NPC1 fibroblasts (Fig. 6) . These proteins are involved in lysosomal vesicle trafficking, which includes lysosome formation, vesicle expansion, and completion during autophagy, SNARE (soluble NSF attachment protein receptor) interactions in vesicular transport, and steroid biosynthesis. As shown in Figure 6 , NPC1 protein was downregulated, while NPC2 protein (Fig. 6B) and lysosomal protein transmembrane 4 alpha (LAPTM4A) were upregulated in NPC1 cells. Unconventional SNARE in the ER 1 (USE1) (Fig. 6C) and the vesicle-associated membrane protein 7 (VAMP7) (Fig. 6D) involved in SNARE interactions in vesicular transport were also dysregulated in the opposite direction in NPC1 fibroblasts. The GABA (A) receptor-associated protein (GABARAP) (Fig. 6E) and GABA (A) receptor-associated protein-like 1 (GABARAPL1) and 2 (GABARAPL2) involved in vesicle expansion and completion 
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during autophagy were all upregulated in NPC1 cells. Several key enzymes involved in steroid biosynthesis, such as NAD (P)-dependent steroid dehydrogenase-like (NSDHL) and 24-dehydrocholesterol reductase (DHCR24) were also overexpressed in NPC1 cells (Fig. 6A, F, and G) . The expression changes of these 19 proteins in NPC1 cells were also confirmed in a repeat proteomic MS experiment. After treatment of NPC1 cells with MbCD-3 for 4 days, the increased NPC2 level was significantly reduced, while there was no significant effect on the decreased NPC1 level (Fig. 6B) . These results are consistent with previous reports that NPC1 protein level was not affected by treatment with cyclodextrin, although cyclodextrin reduced lysosomal cholesterol accumulation. 27 The decrease in elevated NPC2 level in NPC1 cells could result from the MbCD reduction of cholesterol accumulation and improvement of cholesterol trafficking. The dysregulated USE1 (Fig. 6C) , VAMP7 (Fig. 6D) , GABARAP (Fig. 6E) , NSDHL (Fig. 6F) , and DHCR24 (Fig. 6G) were also recovered after MbCD treatments. Similar to the observed pharmacological activities, different batches of MbCDs showed varied effectiveness on the return to normal expression levels of these 19 dysregulated proteins. MbCD-3 exhibited a much better recovery in NPC1 fibroblasts when compared with MbCD-1 and -2, consistent with the observation of the highest reduction of unesterified cholesterol level by MbCD-3. Together, the results of mass spectrum analysis, pharmacological activity measurements (filipin staining, Amplex Red cholesterol determination, and LysoTracker dye staining), and proteomic profiling analysis demonstrate that MbCD-3 is the most efficacious preparation among the three tested.
DISCUSSION
Cyclodextrin is a mixture of different isoforms with differing amounts of substitute groups. In contrast to traditional small molecule drugs, it is impossible to obtain a pure molecule of cyclodextrin. Therefore, the distinct batches of cyclodextrins have different numbers of substitute groups and variations in the average molecular weights. We examined the mass spectrum profiles of three MbCD preparations. We empirically found that they have varying average molecular weights and fluctuating amounts of substitute groups, even though two of them with different lot numbers were obtained from the same vendor with the same catalog number. These three MbCD preparations also exhibited altered pharmacological activity with varied efficacy on reduction of lysosomal cholesterol accumulation. These differences continued on through the ability of the various MbCDs to ameliorate dysregulated protein expression in NPC1 cells. These findings indicate the necessity of employing an analytical method to profile different cyclodextrin preparations to select the qualified one for therapeutic applications.
Cyclodextrin's activity on reduction of lysosomal cholesterol accumulation has been extensively examined in NPC1 cells and animal models. [24] [25] [26] [27] In addition, HPbCD is currently in clinical trials for the treatment of NPC1 disease. 28, 29 The mechanism of cyclodextrins on the reduction of lysosomal cholesterol accumulation and decrease of enlarged lysosomes has been linked to enhancement of lysosomal exocytosis and efflux of cholesterols out of cells. 24, 34 The effect of cyclodextrins on autophagy was also reported; this may contribute to its activity on the reduction of lysosomal lipid accumulation in NPC1 cells. 46 Therefore, cyclodextrins may also have the potential for treatment of other lysosomal storage diseases.
Variable potencies and activities of cyclodextrins have been encountered and reported that may be related to different cells, different assays, and different sources of cyclodextrins. It has been found that the effects of cyclodextrins on autophagosome formation varied on different days after the treatment with cyclodextrins. 47 The autophagosome level increased in the first 2 days after the treatment in NPC1 patient cells and then reduced to a similar level as WT cells. Different cells and tissues as well as different assays may also cause variable responses that have been reported elsewhere. 4, [30] [31] [32] [33] [34] 47 In this study, we report the variable pharmacological effects of cyclodextrin due to the manufacture sources and batches of cyclodextrins.
To avoid the discrepancy in measurements of cyclodextrin's potency and efficacy in both in vitro and in vivo experiments due to the chemical components in cyclodextrins, it is important to set up a standard analytical method for selection of high-quality cyclodextrin for pharmacological experiments and clinical trials. We obtained three preparations of MbCDs from two commercial vendors and tested them in a series of analytical and pharmacological experiments. The mass spectrum analysis showed that different batches of MbCDs have different molecular weights with a unique combination of In addition to the pharmacological experiment, we determined the MbCD effect on protein expression in the patient cells. We have selected and focused on a subset of 19 proteins that are dysregulated in NPC1 patient fibroblasts compared with the WT control cells. These 19 cellular proteins involve in lysosome formation, vesicle expansion, and completion during autophagy, SNARE interactions in vesicular transport, and steroid biosynthesis. Similar to the observed pharmacological activities, different batches of MbCDs showed varied effects on recovery degree of expression of these 19 dysregulated proteins. MbCD-3 exhibited much better recovery of these dysregulated proteins in NPC1 fibroblasts compared with MbCD-1 and -2, consistent with the observation of the highest reduction of unesterified cholesterol level by MbCD-3.
In conclusion, we have developed a set of experimental methods to characterize different preparations of MbCD for selection of an appropriate one for use as a therapeutic agent. The mass spectrum analysis can reveal profiles of average molecular weight and side-chain methylation levels in different MbCD preparations. The pharmacological experiments include filipin cholesterol staining, Amplex Red cholesterol determination, and LysoTracker dye staining for enlarged lysosomes. The proteomic protein expression analysis examines the effect of different cyclodextrin preparations on the signature of dysregulated protein expression levels in NPC1 cells. The combination of these techniques provides more details of the characteristic properties of a specific preparation of cyclodextrin. This new approach has potential to be used as a quality control method for selection of efficacious cyclodextrin to be used as a therapeutic agent for treatment of NPC and other lysosomal storage diseases.
